VSTM5: A Potential Drug Target (G387804)
VSTM5: A Potential Drug Target
VSTM5, or V-set and transmembrane domain containing 5, is a protein that has been identified as a potential drug target and biomarker. It is a member of the voltage-sensitive ion channel (VSC) family, which is a subgroup of the large superfamily of ion channels. VSTM5 is unique due to its structure, which consists of a voltage-sensitive ion channel that is embedded within a transmembrane domain.
The VSTM5 protein is found in various organisms, including bacteria, archaea, and eukaryotes. It is expressed in high abundance in the heart, brain, and nervous system, and is also found in the testes and placenta.
Functions and Interactions
VSTM5 is a voltage-sensitive ion channel that is involved in the regulation of ion traffic in various organ systems. It is highly selective for different types of ions, such as Na+, K+, and Cl- ions. These ions are essential for maintaining the electrical activity of the cells and are involved in various physiological processes, including muscle contractions, nerve impulses, and brain function.
VSTM5 is activated by changes in the membrane potential, which is the difference between the inside and outside of the membrane. When the membrane potential changes, VSTM5 opens its channels, allowing the ions to flow into or out of the cell. This process is critical for maintaining the electrical activity of the cells and is involved in various physiological processes.
VSTM5 is also involved in the regulation of ion transport in the brain and nervous system. It is expressed in high abundance in the brain and has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity.
Drug Targeting
VSTM5 is a drug target of great interest due to its unique structure and its involvement in various physiological processes. Drugs that can modulate the activity of VSTM5 have the potential to treat a variety of diseases.
One of the main targets of drugs that can modulate the activity of VSTM5 is the voltage-sensitive ion channel itself. Drugs that can modulate the opening or closing of the channels can be used to treat a variety of disorders, including epilepsy, bipolar disorder, and neurodegenerative diseases.
Another target of drugs that can modulate the activity of VSTM5 is its role in the regulation of ion transport. Drugs that can modulate the activity of VSTM5 can be used to treat a variety of disorders, including salt craving, hyperkalemia, and hypoosmolality.
Another potential target of drugs that can modulate the activity of VSTM5 is its role in the regulation of neuronal excitability. Drugs that can modulate the activity of VSTM5 can be used to treat a variety of disorders, including neuropsychiatric disorders, such as depression and anxiety.
Conclusion
VSTM5 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various physiological processes make it an attractive target for drugs that can modulate its activity. Further research is needed to fully understand the function and interactions of VSTM5 and to develop effective treatments for the various disorders that it is involved in.
Protein Name: V-set And Transmembrane Domain Containing 5
Functions: Cell adhesion-like membrane protein of the central nervous system (CNS) which modulates both the position and complexity of central neurons by altering their membrane morphology and dynamics. Involved in the formation of neuronal dendrites and protrusions including dendritic filopodia. In synaptogenesis, regulates synapse formation by altering dendritic spine morphology and actin distribution. Promotes formation of unstable neuronal spines such as thin and branched types. Regulates neuronal morphogenesis and migration during cortical development in the brain
The "VSTM5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSTM5 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
VSX1 | VSX2 | VTA1 | VTCN1 | VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B
